» Articles » PMID: 18785621

Surveillance for Hepatocellular Carcinoma in Patients with Primary Biliary Cirrhosis

Overview
Journal Hepatology
Specialty Gastroenterology
Date 2008 Sep 13
PMID 18785621
Citations 17
Authors
Affiliations
Soon will be listed here.
Abstract

Unlabelled: Hepatocellular carcinoma (HCC) occurs with increased frequency in patients with primary biliary cirrhosis (PBC). Effectiveness of surveillance recommendations for HCC is controversial, and data are lacking in patients with PBC. In this study, we attempt to (1) establish the importance of surveillance for HCC in patients with PBC; (2) identify a target population of patients with PBC for HCC surveillance; and (3) propose surveillance recommendations for patients with PBC. We retrospectively identified 36 patients seen at the Mayo Clinic between 1976 and 2007 with a diagnosis of both PBC and HCC. Five patients (14%) were diagnosed incidentally, 17 patients comprised our surveillant population, and 14 patients were diagnosed outside a surveillance program. Patients in the surveillant population were more likely to undergo therapy (88% versus 43%; P = 0.01) and had improved survival (P = 0.002) compared with the nonsurveillant population. All cases of HCC except one were predicted to be at significant risk for HCC based on age, sex, evidence of portal hypertension, and history of blood transfusion using a previous predictive model.

Conclusion: We established the importance of surveillance for HCC in patients with PBC. We demonstrated adequate performance of a predictive model and propose it should be refined and used to identify patients with PBC who should be screened for development of HCC. Further studies are needed so that optimal HCC surveillance recommendations in this population can be determined and included in the practice guidelines for PBC.

Citing Articles

Risk of Cancer and Subsequent Mortality in Primary Biliary Cholangitis: A Population-based Cohort Study of 3052 Patients.

Schonau J, Wester A, Schattenberg J, Hagstrom H Gastro Hep Adv. 2024; 2(7):879-888.

PMID: 39130771 PMC: 11307889. DOI: 10.1016/j.gastha.2023.05.004.


Benefits and harms of screening for hepatocellular carcinoma in high-risk populations: systematic review and meta-analysis.

Yang J, Yang Z, Zeng X, Yu S, Gao L, Jiang Y J Natl Cancer Cent. 2024; 3(3):175-185.

PMID: 39035193 PMC: 11256723. DOI: 10.1016/j.jncc.2023.02.001.


Hepatocellular carcinoma in primary sclerosing cholangitis and primary biliary cholangitis: a clinical and pathological study in an uncommon but emerging setting.

Bosch D, Zen Y, Boukhar S, Liu Y, Cheng L, Yeh M Virchows Arch. 2021; 479(6):1131-1143.

PMID: 34414507 DOI: 10.1007/s00428-021-03183-6.


A Practical Review of Primary Biliary Cholangitis for the Gastroenterologist.

Onofrio F, Hirschfield G, Gulamhusein A Gastroenterol Hepatol (N Y). 2019; 15(3):145-154.

PMID: 31061656 PMC: 6495411.


Hepatocellular carcinoma surveillance: An evidence-based approach.

Harris P, Hansen R, Gray M, Massoud O, McGuire B, Shoreibah M World J Gastroenterol. 2019; 25(13):1550-1559.

PMID: 30983815 PMC: 6452232. DOI: 10.3748/wjg.v25.i13.1550.